Loading...
XJPX
4570
Market cap62mUSD
Oct 09, Last price  
1,072.00JPY
1D
0.94%
1Q
7.20%
Jan 2017
32.67%
IPO
35.18%
Name

Immuno-Biological Laboratories Co Ltd

Chart & performance

D1W1MN
XJPX:4570 chart
P/E
30.35
P/S
9.93
EPS
35.33
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
10.77%
Revenues
1.00b
+3.66%
576,000,000602,749,000647,576,000794,621,000816,701,000969,533,0001,004,987,000
Net income
329m
+32.11%
-668,000,000-318,827,000-258,767,000-289,731,000186,694,000249,047,000329,015,000
CFO
301m
+64.09%
-608,000,000-194,145,000-93,204,00026,458,000133,775,000183,495,000301,093,000
Dividend
Mar 30, 20277.5 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.

Key people

Shoko Onodera
Director of Human Resources and General Affairs, Manager of Internal Audit Office, President of Subsidiary, Director · since 2013
Yoshiaki Hagiwara
Executive Officer · since 2025
Daisuke Kawase
Executive Officer · since 2024
Tatsuya Segawa
Executive Officer · since 2024
Ayano Tsuburaya
Executive Officer · since 2024
Masato Nakagawa
Managing Director, Managing Executive Officer, Chief Director of Business Group Administration · since 2021
Independent Director · since 2011
Ikkei Kojima
Independent Director · since 2019
IPO date
Mar 02, 2007
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT